Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)

PHASE4CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions
Multiple Sclerosis
Interventions
DRUG

Mavenclad®

This low interventional extension study involves the follow up of participants in the parent study. The participants were followed up for an additional 2 year period (until 4 years after initial administration of Mavenclad® tablets), during which the participants were not treated with Mavenclad®, as per European Medicines Agency (EMA) label of Mavenclad®.

Trial Locations (60)

Unknown

Eva Maida, Vienna

FN u sv. Anny Brno, Brno

FN Hradec Králové, Hradec Králové

Nemocnice Jihlava, p.o., Jihlava

Fakultni nemocnice Olomouc, Olomouc

Fakultni nemocnice Ostrava, Ostrava

Faculty Hospital Kralovske Vinohrady, Prague

Vseobecna fakultni nemocnice v Praze, Prague

Nemocnice Teplice, Teplice

Glostrup Sygehus, Glostrup Municipality

Odense Univeristy Hospital, Odense

Centre hospitalier de la Côte Basque - Saint Léon, Bayonne

Pellegrin, Bordeaux

CHU de la Côte de Nacre, Caen

Centre Hospitalier de Gonesse, Gonesse

CHRU de Lille Hôpital Roger Salengro, Lille

CHU Hôpital Nord Laennec, Nantes

Hôpital de la Pitié-Salpétrière, Paris Cédex 13

CHU de Poissy, Poissy

Centre Universitaire de Rouen, Rouen

CHU Tours - Hôpital Bretonneau, Tours

Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet, Budapest

Semmelweis University II, Budapest

Uzsoki Utcai Korhaz, Budapest

Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen

Valeomed Kft, Esztergom

Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór, Nyíregyháza

A.O.U. Ospedali Riuniti Umberto, Ancona

University of Cagliari, Cagliari

PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania, Catania

Ospedale San Raffaele Giglio, Cefalù

"Instituto Nazionale Neurologico Carlo Besta", Milan

Ospedale San Raffaele, IRCCS, Milan

A.O. Universitaria Federico II, Napoli

Policlinico Università della Campania L. Vanvitelli, Napoli

A.O. Ospedali Riuniti Villa Sofia-Cervello U.O. Endocrinolog, Palermo

Azienda Ospedaliera S. Camillo Forlanini, Roma

Neurological Center of Latium, Roma

Ospedale Sant'Andrea Neurologia - Università La Sapienza, Roma

Policlinico Tor Vergata, Roma

Zuyderland, Sittard-Geleen

COPERNICUS Podmiot Leczn. Sp z o.o., Gdansk

M.A.-Lek A.M. Maciejowscy S.C. Centrum Terapii SM, Katowice

Centrum Neurologii Krzysztof Selmaj, Lodz

Uniwersytecki Szpital Kliniczny nr 1 i.m. Norberta Barlickie, Lodz

Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin

Centrum Medyczne Medyk, Rzeszów

Instytut Psychiatrii i Neurologii - Dept of Neurology II, Warsaw

Neuropoint s.r.o, Bratislava

Univerzitna nemocnica Martin, Martin

Fakultna nemocnica Nitra, Nitra

Fakultna nemocnica Trnava, Trnava

Hospital Universitario de Getafe, Getafe

C.A.U. de León - H. de León, León

Hospital Arnau de Vilanova, Lleida

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Virgen de la Arrixaca, Murcia

Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí

Hospital Universitario Nuestra Senora de la Candelaria, Santa Cruz de Tenerife

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04776213 - Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension) | Biotech Hunter | Biotech Hunter